The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis

Diabetic Medicine

Volumn 20, Issue 1, 2003, Pages 3-15

  Holt, Richard I G ^a,c   Simpson, H L ^b   Sonksen P H ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Glucose metabolism; Growth hormone; Growth hormone deficiency; Insulin resistance; Insulin like growth factor

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATE; GROWTH HORMONE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PEGVISOMANT; PHOSPHOTRANSFERASE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C;

ACROMEGALY; ARTHRALGIA; DIABETIC MICROANGIOPATHY; DIABETIC OBESITY; DISEASE COURSE; GENE DELETION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HEADACHE; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LARON SYNDROME; METABOLIC SYNDROME X; MICROANGIOPATHY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NON ISLET CELL TUMOR HYPOGLYCEMIA; NONHUMAN; PARANEOPLASTIC SYNDROME; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIDE EFFECT; SUBSTITUTION THERAPY; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; GROWTH HORMONE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR I;

EID: 0037232337     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.00827.x     Document Type: Review

References (148)

1. Houssay BA, Biasotti A. La diabetes pancreatica de los perros hipofiseoprivos. Rev Soc Argent Biol 1930; 6: 251-296.
2. Young FG. Anterior pituitary fraction and carbohydrate metabolism I; the preparation and properties of diabetogenic extracts. J Endocrinol 1939; 1: 339-354.
3. Young FG. 'Growth' and the diabetogenic action of anterior pituitary preparations. BMJ 1941; 2: 897-901.
4. Luft R, Ikkos D, Gemzell CA, Olivercrona H, Sjogren B. The effects of growth hormone in man. Lancet 1958; 1: 720-721.
5. Zierler K, Rabinomitz R. Roles of insulin and growth hormone based on studies of forearm metabolism in man. Medicine 1963; 42: 385-395.
6. Tamborlane WV, Sherwin RS, Koivisto V, Hendler R, Genel M, Felig P. Normalization of the growth hormone and catecholamine response to exercise in juvenile-onset diabetic subjects treated with a portable insulin infusion pump. Diabetes 1979; 28: 785-788.
7. Bak JF, Moller N, Schmitz O. Effects of growth hormone on fuel utilization and muscle glycogen synthase activity in normal humans. Am J Physiol 1991; 260: E736-742.
8. Press M, Tamborlane WV, Sherwin RS. Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. N Eng J Med 1984; 310: 810-815.
9. Fowelin J, Attvall S, von Schenck H, Smith U, Lager I. Characterization of the insulin-antagonistic effect of growth hormone in insulin-dependent diabetes mellitus. Diabet Med 1995; 12: 990-996.
10. Fowelin J, Attvall S, von Schenck H, Smith U, Lager I. Characterization of the insulin-antagonistic effect of growth hormone in man. Diabetologia 1991; 34: 500-506.
11. Gerich JE, Lorenzi M, Bier DM, Tsalikian E, Schneider V, Karam JH et al. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. J Clin Invest 1976; 57: 875-884.
12. Randle PJ, Hales CN, Garland PB, Newsholme EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbance of diabetes mellitus. Lancet 1963; i: 785-789.
13. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983; 72: 1737-1747.
14. Hansen AP, Johansen K. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia 1970; 6: 27-33.
15. Navalesi R, Pilo A, Vigneri R. Growth hormone kinetics in diabetic patients. Diabetes 1975; 24: 317-327.
16. Wurzburger MI, Prelevic GM, Sonksen PH, Peric LA, Till S, Morris RW. The effects of improved blood glucose on growth hormone and cortisol secretion in insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf) 1990; 32: 787-797.
17. Wurzburger MI, Prelevic GM, Sonksen PH. Restoration of hypoglycaemia awareness by human recombinant growth hormone. Lancet 1992; 339: 496-497.
18. Wurzburger MI, Prelevic GM, Sonksen PH, Balint-Peric LA, Wheeler M. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J Clin Endocrinol Metab 1993; 77: 267-272.
19. Wurzburger MI, Prelevic GM, Sonksen PH, Wheeler M, Balint-Peric L. Effect of recombinant human growth hormone treatment on insulin-like growth factor (IGF-I) levels in insulin-dependent diabetic patients. Acta Diabetologica 1995; 32: 131-134.
20. Campbell PJ, Bolli GB, Cryer PE, Gerich JE. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Eng J Med 1985; 312: 1473-1479.
21. Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P et al. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 1991; 34: 21-28.
22. Boyle PJ, Avogaro A, Smith L, Shah SD, Cryer PE, Santiago JV. Absence of the dawn phenomenon and abnormal lipolysis in type 1 (insulin-dependent) diabetic patients with chronic growth hormone deficiency. Diabetologia 1992; 35: 372-379.
23. Poulsen JE. Houssay phenomenon in man: recovery form retinopathy in a case of diabetes with Simmonds disease. Diabetes 1953; 2: 7-12.
24. Wright AD, Kohner EM, Oakley NW, Hartog M, Joplin GF, Fraser TR. Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation. BMJ 1969; 2: 346-348.
25. Lundbaek K, Christensen NJ, Jensen VA, Johansen K, Olsen TS, Hansen AP et al. Diabetes, diabetic angiopathy, and growth hormone. Lancet 1970; 2: 131-133.
26. Sonksen PH, Russell-Jones D, Jones RH. Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future? Hormone Res 1993; 40: 68-79.
27. Sharp PS, Fallon TJ, Brazier OJ, Sandler L, Joplin GF, Kohner EM. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 1987; 30: 199-207.
28. Alzaid AA, Dinneen SF, Melton LJ, Rizza RA. The role of growth hormone in the development of diabetic retinopathy. Diabetes Care 1994; 17: 531-534.
29. Blank D, Riedl M, Reitner A, Schnack C, Schernthaner G, Clodi M et al. Growth hormone replacement therapy is not associated with retinal changes. J Clin Endocrinol Metab 2000; 85: 634-636.
30. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM. A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy. Metabolism 1989; 38: 586-589.
31. Flyvbjerg A. Growth factors and diabetic complications. Diabet Med 1990; 7: 387-399.
32. Chiarelli F, Santilli F, Mohn A. Role of growth factors in the development of diabetic complications. Hormone Res 2000; 53: 53-67.
33. Janssen JA, Lamberts SW. Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxf) 2000; 52: 1-9.
34. Valera A, Rodriguez-Gil JE, Yun JS, McGrane MM, Hanson RW, Bosch F. Glucose metabolism in transgenic mice containing a chimeric P-enolpyruvate carboxykinase/bovine growth hormone gene. FASEB J 1993; 7: 791-800.
35. Ikeda A, Chang KT, Matsumoto Y, Furuhata Y, Nishihara M, Sasaki F et al. Obesity and insulin resistance in human growth hormone transgenic rats. Endocrinology 1998; 139: 3057-3063.
36. Balbis A, Dellacha JM, Calandra RS, Bartke A, Turyn D. Down regulation of masked and unmasked insulin receptors in the liver of transgenic mice expressing bovine growth hormone gene. Life Sci 1992; 51: 771-778.
37. Balbis A, Bartke A, Turyn D. Overexpression of bovine growth hormone in transgenic mice is associated with changes in hepatic insulin receptors and in their kinase activity. Life Sci 1996; 59: 1363-1371.
38. Dominici FP, Cifone D, Bartke A, Turyn D. Alterations in the early steps of the insulin-signaling system in skeletal muscle of GH-transgenic mice. Am J Physiol 1999; 277: E447-454.
39. Dominici FP, Cifone D, Bartke A, Turyn D. Loss of sensitivity to insulin at early events of the insulin signaling pathway in the liver of growth hormone-transgenic mice. J Endocrinol 1999; 161: 383-392.
40. Dominici FP, Balbis A, Bartke A, Turyn D. Role of hyperinsulinemia on hepatic insulin receptor concentration and autophosphorylation in the presence of high growth hormone levels in transgenic mice overexpressing growth hormone gene. J Endocrinol 1998; 159: 15-25.
41. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73: 233-240.
42. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000; 85: 193-199.
43. Sonksen PH, Greenwood FC, Ellis JP, Lowy C, Rutherford A, Nabarro JD. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab 1967; 27: 1418-1430.
44. Sonksen PH. Aetiology and epidemiology of diabetes. Br J Hosp Med 1972; 7: 151-156.
45. Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 1994; 130: 581-586.
46. Parkinson C, Trainer PJ. GH receptor antagonists in acromegaly. Proc Am Endocrine Soc Conference 2001: 58.1.
47. Muller AF, Leebeek FW, Janssen JA, Lamberts SW, Hofland L, van der Lely AJ. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency. J Clin Endocrinol Metab 2001; 86: 5165-5171.
48. Salomon F, Cuneo RC, Umpleby AM, Sonksen PH. Interactions of body fat and muscle mass with substrate concentrations and fasting insulin levels in adults with growth hormone deficiency. Clin Sci (Lond) 1994; 87: 201-206.
49. Salomon F, Cuneo RC, Umpleby AM, Sonksen PH. Glucose and fat metabolism in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 1994; 41: 315-322.
50. Alford FP, Hew FL, Christopher MC, Rantzau C. Insulin sensitivity in growth hormone (GH)-deficient adults and effect of GH replacement therapy. J Endocrinol Invest 1999; 22: 28-32.
51. Hew FL, Koschmann M, Christopher M, Rantzau C, Vaag A, Ward G et al. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab 1996; 81: 555-564.
52. Rosenfalck AM, Fisker S, Hilsted J, Dinesen B, Volund A, Jorgensen JO et al. The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy. Growth Horm IGF Res 1999; 9: 96-105.
53. Fowelin J, Attvall S, Lager I, Bengtsson BA. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993; 42: 1443-1447.
54. O'Neal DN, Kalfas A, Dunning PL, Christopher MJ, Sawyer SD, Ward GM et al. The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. J Clin Endocrinol Metab 1994; 79: 975-983.
55. Rosenfalck AM, Maghsoudi S, Fisker S, Jorgensen JO, Christiansen JS, Hilsted J et al. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 2000; 85: 4173-4181.
56. Salomon F, Umpleby AM, Cuneo RC, Sönksen PH. Protein, fat and glucose metabolism during treatment with recombinant human growth hormone in adults with growth hormone deficiency. Short and long term effects. Endocrinol Metab 1997; 4: 121-128.
57. Riedl M, Ludvik B, Pacini G, Clodi M, Kotzmann H, Wagner O et al. The increased insulin sensitivity in growth hormone-deficient adults is reduced by growth hormone replacement therapy. Eur J Clin Invest 2000; 30: 771-778.
58. al Shoumer KA, Gray R, Anyaoku V, Hughes C, Beshyah S, Richmond W et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol (Oxf) 1998; 48: 795-802.
59. Chrisoulidou A, Beshyah SA, Rutherford O, Spinks TJ, Mayet J, Kyd P et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metabol 2000; 85: 3762-3769.
60. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999; 84: 2596-2602.
61. Fink RI, Kolterman OG, Griffin J, Olefsky JM. Mechanisms of insulin resistance in aging. J Clin Invest 1983; 71: 1523-1535.
62. Monson JP, Bengtsson BA, Abs R, Feldt-Rasmussen U, Wuster C. Can growth hormone therapy cause diabetes? KIMS Strategic Committee. Lancet 2000; 355: 1728-1729.
63. Wilton P. Review of KIMS data. Proceedings of the Am Endo Soc Conference 2001.
64. Hartman ML. Review of HypoCCS data. Proceedings of the Am Endo Soc Conference 2001.
65. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
66. Johannsson G, Bengtsson BA. Growth hormone and the metabolic syndrome. J Endocrinol Invest 1999; 22: 41-46.
67. Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991; 72: 51-59.
68. Holt RIG, Webb E, Pentecost C, Sönksen PH. Ageing and physical fitness are more important than obesity in determining exercise induced generation of growth hormone. J Clin Endocrinol Metab 2001; 86: 5715-5720.
69. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997; 82: 727-734.
70. D'Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 1984; 81: 935-939.
71. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999; 96: 7324-7329.
72. Mathews LS, Hammer RE, Brinster RL, Palmiter RD. Expression of insulin-like growth factor I in transgenic mice with elevated levels of growth hormone is correlated with growth. Endocrinology 1988; 123: 433-437.
73. Russell-Jones DL, Rattray M, Wilson VJ, Jones RH, Sonksen PH, Thomas CR. Intraperitoneal insulin is more potent than subcutaneous insulin at restoring hepatic insulin-like growth factor-I mRNA levels in the diabetic rat: a functional role for the portal vascular link. J Mol Endocrinol 1992; 9: 257-263.
74. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15: 80-101.
75. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75: 59-72.
76. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990; 345: 78-80.
77. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73-82.
78. Lamothe B, Baudry A, Desbois P, Lamotte L, Bucchini D, De Meyts P et al. Genetic engineering in mice: impact on insulin signalling and action. Biochem J 1998; 335: 193-204.
79. Sjogren K, Wallenius K, Liu JL, Bohlooly YM, Pacini G, Svensson L et al. Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. Diabetes 2001; 50: 1539-1545.
80. Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J et al. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001; 50: 1110-1118.
81. Jacob R, Barrett E, Plewe G, Fagin KD, Sherwin RS. Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin. J Clin Invest 1989; 83: 1717-1723.
82. Shojaee-Moradie F, Umpleby AM, Thomason MJ, Jackson NC, Boroujerdi MA, Sonksen PH et al. A comparison of the effects of insulin-like growth factor-I, insulin and combined infusions of insulin and insulin-like growth factor-I on glucose metabolism in dogs. Eur J Clin Invest 1995; 25: 920-928.
83. Froesch ER, Burgi H, Ramseier EB, Bally P, Labhart A. Antibody suppressible and non-suppressible insulin-like activities in human serum and their physiological significance. An insulin assay with adipose tissue of increased precision and specificity. J Clin Invest 1963; 42: 1816-1834.
84. Froesch ER. The physiology and pharmacology of adipose tissue lipolysis: its inhibition and implications for the treatment of diabetes. Diabetologia 1967; 3: 475-487.
85. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-2776.
86. Zenobi PD, Graf S, Ursprung H, Froesch ER. Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest 1992; 89: 1908-1913.
87. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Eng J Med 1987; 317: 137-140.
88. Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. Am J Physiol 1992; 262: E130-133.
89. Turkalj I, Keller U, Ninnis R, Vosmeer S, Stauffacher W. Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab 1992; 75: 1186-1191.
90. Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest 1994; 93: 1131-1139.
91. Russell-Jones DL, Bates AT, Umpleby AM, Hennessy TR, Bowes SB, Hopkins KD et al. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur J Clin Invest 1995; 25: 403-411.
92. Scott CD, Baxter RC. Production of insulin-like growth factor I and its binding protein in rat hepatocytes cultured from diabetic and insulin-treated diabetic rats. Endocrinology 1986; 119: 2346-2352.
93. Boni-Schnetzler M, Schmid C, Meier PJ, Froesch ER. Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am J Physiol 1991; 260: E846-851.
94. Maes M, Underwood LE, Ketelslegers JM. Low serum somatomedin-C in insulin-dependent diabetes: evidence for a postreceptor mechanism. Endocrinology 1986; 118: 377-382.
95. Goya L, de la Puente A, Ramos S, Martin MA, Escriva F, Alvarez C et al. Regulation of IGF-I and -II by insulin in primary cultures of fetal rat hepatocytes. Endocrinology 2001; 142: 5089-5096.
96. Amiel SA, Sherwin RS, Hintz RL, Gertner JM, Press CM, Tamborlane WV. Effect of diabetes and its control on insulin-like growth factors in the young subject with type I diabetes. Diabetes 1984; 33: 1175-1179.
97. Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, Tauber M, Bastide R, Chale JJ et al. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM. Diabetologia 1996; 39: 1498-1504.
98. Carroll PV, Umpleby M, Ward GS, Imuere S, Alexander E, Dunger D et al. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM. Diabetes 1997; 46: 1453-1458.
99. Cheetham TD, Jones J, Taylor AM, Holly J, Matthews DR, Dunger DB. The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 678-681.
100. Acerini CL, Harris DA, Matyka KA, Watts AP, Umpleby AM, Russell-Jones DL et al. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. Metabolism 1998; 47: 1481-1489.
101. Carroll PV, Christ ER, Umpleby AM, Gowrie I, Jackson N, Bowes SB et al. IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. Diabetes 2000; 49: 789-796.
102. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997; 350: 1199-1204.
103. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000; 85: 1518-1524.
104. Simpson HL, Jackson N, Croos P, Shojaee-Moradie F, Russell-Jones DL, Jones R et al. IGF-I has an independent effect on glucose metabolism in type 1 diabetes. Proceedings of the Am Endo Soc Conference 2001: OR44-1.
105. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992; 90: 2234-2241.
106. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996; 45: 91-100.
107. Frystyk J, Hussain M, Skjaerbaek C, Porksen N, Froesch ER, Orskov H. The pharmacokinetics of free insulin-like growth factor-I in healthy subjects. Growth Horm IGF Res 1999; 9: 150-156.
108. Clemmons DR, Moses A, Jacobson W, Rogol A, Sommer A, Allan G. IGF-I/IGFBP3 by injection or infusion to type 2 diabetes increases free IGF-I and reduces insulin requirements. Proceedings of the Am Endo Soc Conference 2001: OR9-4.
109. Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J et al. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Invest 1994; 94: 1126-1133.
110. Mauras N, O'Brien KO, Welch S, Rini A, Helgeson K, Vieira NE et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 2000; 85: 1686-1694.
111. Usala AL, Madigan T, Burguera B, Sinha MK, Caro JF, Cunningham P et al. Brief report: treatment of insulin-resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes. N Eng J Med 1992; 327: 853-857.
112. Quin JD, Fisher BM, Paterson KR, Inoue A, Beastall GH, MacCuish AC. Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome. N Eng J Med 1990; 323: 1425-1426.
113. Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 1991; 34: 675-679.
114. Zenobi PD, Glatz Y, Keller A, Graf S, Jaeggi-Groisman SE, Riesen WF et al. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 1994; 131: 251-257.
115. Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 1994; 79: 205-210.
116. Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract 1995; 28: S185-194.
117. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993; 42: 696-705.
118. Di Cola G, Cool MH, Accili D. Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 1997; 99: 2538-2544.
119. Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Metabolism: 1995; 44: 113-118.
120. Laron Z. The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome. J Clin Endocrinol Metab 1999; 84: 4397-4404.
121. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Eng J Med 1996; 335: 1363-1367.
122. Woods KA, Camacho-Hubner C, Bergman RN, Barter D, Clark AJ, Savage MO. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 2000; 85: 1407-1411.
123. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
124. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999; 20: 761-787.
125. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994; 79: 872-878.
126. Holly JM, Biddlecombe RA, Dunger DB, Edge JA, Amiel SA, Howell R et al. Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin. A new role for insulin? Clin Endocrinol (Oxf) 1988; 29: 667-675.
127. Batch JA, Baxter RC, Werther G. Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes. J Clin Endocrinol Metab 1991; 73: 964-968.
128. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC. Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 1991; 129: 2254-2256.
129. Baxter RC, Hizuka N, Takano K, Holman SR, Asakawa K. Responses of insulin-like growth factor binding protein-1 (IGFBP-1) and the IGFBP-3 complex to administration of insulin-like growth factor-I. Acta Endocrinol (Copenh) 1993; 128: 101-108.
130. Frystyk J, Hussain M, Skjaerbaek C, Schmitz O, Christiansen JS, Froesch ER et al. Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline. Am J Physiol 1997; 273: E507-513.
131. Holt RIG, Jones JS, Stone NM, Baker AJ, Miell JP. Sequential changes in insulin-like growth factor I (IGF-I) and IGF-binding proteins in children with end-stage liver disease before and after successful orthotopic liver transplantation. J Clin Endocrinol Metab 1996; 81: 160-168.
132. Holt RIG, Miell JP, Jones JS, Mieli-Vergani G, Baker AJ. Nasogastric feeding enhances nutritional status in paediatric liver disease but does not alter circulating levels of IGF-I and IGF binding proteins. Clin Endocrinol (Oxf) 2000; 52: 217-224.
133. Rajkumar K, Krsek M, Dheen ST, Murphy LJ. Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice. J Clin Invest 1996; 98: 1818-1825.
134. Crossey PA, Jones JS, Miell JP. Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes 2000; 49: 457-465.
135. Rajkumar K, Dheen ST, Murphy LJ. Hyperglycemia and impaired glucose tolerance in IGF binding protein-1 transgenic mice. Am J Physiol 1996; 270: E565-571.
136. Rajkumar K, Murphy LJ. Enhanced gluconeogenesis and hepatic insulin resistance in insulin-like growth factor binding protein-1 transgenic mice. Biochim Biophys Acta 1999; 1426: 491-497.
137. Hoeflich A, Wu M, Mohan S, Foll J, Wanke R, Froehlich T et al. Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology 1999; 140: 5488-5496.
138. Zapf J. Role of insulin-like growth factor (IGF) II and IGF binding proteins in extrapancreatic tumour hypoglycaemia. J Int Med 1993; 234: 543-552.
139. Joffe B, Kew M, Beaton G, Kusman B, Seftel H. Serum somatomedin and insulin levels in tumor hypoglycemia. J Endocrinol Invest 1978; 1: 269-271.
140. Baxter RC, Daughaday WH. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. J Clin Endocrinol Metab 1991; 73: 696-702.
141. Daughaday WH, Trivedi B, Baxter RC. Serum 'big insulin-like growth factor II' from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing. Proc Natl Acad Sci USA 1993; 90: 5823-5827.
142. Reeve AE, Eccles MR, Wilkins RJ, Bell GI, Millow LJ. Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature 1985; 317: 258-260.
143. Ron D, Powers AC, Pandian MR, Godine JE, Axelrod L. Increased insulin-like growth factor II production and consequent suppression of growth hormone secretion: a dual mechanism for tumor-induced hypoglycemia. J Clin Endocrinol Metab 1989; 68: 701-706.
144. Zapf J, Futo E, Peter M, Froesch ER. Can 'big' insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest 1992; 90: 2574-2584.
145. Katz LE, Liu F, Baker B, Agus MS, Nunn SE, Hintz RL et al. The effect of growth hormone treatment on the insulin-like growth factor axis in a child with nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab 1996; 81: 1141-1146.
146. Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Eng J Med 1988; 319: 1434-1440.
147. Frystyk J, Skjaerbaek C, Zapf J, Orskov H. Increased levels of circulating free insulin-like growth factors in patients with nonislet cell tumour hypoglycaemia. Diabetologia 1998; 41: 589-594.
148. Teale JD, Blum WF, Marks V. Alleviation of non-islet cell tumour hypoglycaemia by growth hormone therapy is associated with changes in IGF binding protein-3. Ann Clin Biochem 1992; 29: 314-323.